Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
Kumano, Yohei; Hasegawa, Yoriko; Kawahara, Takashi; Yasui, Masato; Miyoshi, Yasuhide; Matsubara, Nobuaki; Uemura, Hiroji.
Biomed Res Int
; 2019: 9450838, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30800682
Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.
Integrative clinical genomics of advanced prostate cancer.
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.
Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management.
Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications.
No man's land: information needs and resources of men with metastatic castrate resistant prostate cancer.
Targeting molecular resistance in castration-resistant prostate cancer.
First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials.
Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy.
Aggressive variants of castration-resistant prostate cancer.